Background. Cellular transplantation for subacute and chronic spinal cord injury (SCI) continues to proceed around the world, but clinicians and patients have only 10 English language publications of case reports and self-serving Web page anecdotes to guide them. Methods. Recent publications about the use of olfactory ensheathing, bone marrow stromal, and fetal tissue stem cells in human subjects are examined to assess the adequacy of their designs, conclusions, and interpretation. Results. Case series reports to date reveal adverse responses to cellular therapy when clinicians look for these and no clear functional effects when a matched group that is not treated is compared. Rehabilitation that focuses on potential targets for sensorimotor and functional gains must precede a transplantation until a plateau of change is reached and then continue for at least 6 months if not a year. Conclusion. Criteria are listed as the minimum requirements for any further case series reports to be considered by journals in regard to cellular interventions for SCI. Based on available reports, the published interventions should not be given to additional patients. One or two of the strategies can be considered for testing in a randomized trial with blinded assessors and an independent data monitoring committee to examine for biological activity in patients with motor complete SCI of greater than 4 to 6 months duration.
Implantation of pluripotent or progenitor cells to treat spinal cord injury (SCI) has been moving gradually from the bench to the clinic. 1 Journals dedicated to neural repair are likely to receive an increasing number of submissions of nonrandomized, unblinded-observer clinical reports of cellular interventions in subacute and chronically impaired patients. These pilot studies, like others for any rehabilitation intervention, are often less than optimally designed and reported. 2 These reports, however, are closely monitored by highly disabled, vulnerable people and sometimes interpreted laxly by the media. That means that the editorial boards of journals must ponder and balance competing ethical obligationsproviding relevant findings from human experiments while protecting the potential recipients of these interventions from unreliable information.
What minimal qualifications must be met by the authors of a case series about cellular interventions that will enable a journal to consider the report for publication? Submissions to Neurorehabilitation and Neural Repair (NNR), and the recent publication of 2 such reports, 3, 4 along with publications in other journals, suggest a range of considerations and compromises. The following recommendations, drawn from published expert opinions [5] [6] [7] but with extra weight on the additive contribution of clinical information that is not yet available from studies in human subjects, are shown in Table  1 (key participant baseline and interim measurements are given in Tables 2 and 3 ). These minimal criteria may also shine light on the stem cell business spas around the world that only report anecdotes on their Internet sites, rather than participating in well-designed trials. Investigators can consider these criteria when starting their case studies. And patients can look for these criteria in addition to more standard ones (http://www.campaignforcure.org/iccp/index.php? option=com_content&task=view&id=24&Itemid=38) when considering participation in a trial.
Published Trials
The best design to date for a cellular transplantation safety study was by Mackay-Sim et al 9 in Australia. This phase I/IIa design tested the feasibility and safety of transplantation of autologous olfactory ensheathing cells (OECs) into the surrounds of the injured spinal cord in 6 subjects with complete, chronic thoracic SCI; 6 matched subjects did not receive surgery and served as controls for the assessors, who were blinded to the treatment status of the patients. At 3 years, no adverse responses, such as pain and syrinx or tumor formation, were found, and no functional changes emerged. One cell recipient gained light touch and pin prick over 3 segments bilaterally.
Thompson et al 10 in the United States examined the feasibility and safety of injecting fetal spinal cord tissue into the posttraumatic syrinx of 8 patients with chronic SCI. Participants were assessed by a neurophysiological protocol to quantify peripheral nerve function, spinal cord reflex excitability, and conduction by somatosensory evoked potentials. Long-term follow-up with repeated measures revealed no complications or likely efficacy. Their procedures, cell typing, planned assessments, results reporting, and data interpretation left few open-ended questions for the reader.
At the far less valuable end of the spectrum, Huang et al 11, 12 in China described transplantation of fetal OECs into the intramedullary cystic region of 300 patients with complete and incomplete SCI. The cells were derived from the olfactory bulbs of 12-to 16-week-old human fetuses but not shown. These allograft transplants were given without immune suppression. The patients were followed for only 2 to 8 weeks. Huang referred to Email notes and letters initiated by recipients in his lectures to support his sense of improvements 1. The conceptual basis for the intervention is sound, based on preclinical testing 2. Subjects sign an informed consent approved by an academic body 3. The cell type, based on valid markers and quantity, is defined, and the method and location of cell injection is described 4. The population sample is well defined by baseline descriptors and valid impairment and disability tools 5. Clinicians with expertise in spinal cord injury would not anticipate further functionally important gains over time and with rehabilitation 8 6. The study addresses an important scientific or clinical question about transplantation that cannot be learned from animal models 7. The study design and report include an explicit, prospective search at scheduled intervals for plausible and unexpected adverse reactions 8. The design tries to assess for cell survival and plausible biological activity that may be associated with efficacy or lack of efficacy 9. A table of key participant baseline and interim measurements (Tables 2 and 3) is provided for every subject 10. Attempts are made to eliminate bias in the collection of outcomes. Blinded observers who have been trained in the use of measurement tools and who deliver their reports directly to an independent statistical core is the best strategy 11. An independent safety and data monitoring committee reviews every participant's data 12. Assessments include valid behavioral and physiological tools to determine a decline, no change, a subtle difference that suggests possible positive or negative biological activity, and a clinically important apparent change 13. Behavioral and neurophysiological data are collected prospectively, preferably by an observer who is not aware of the timing of the intervention and the type of rehabilitation 14. Preintervention rehabilitation is provided for at least 20 hours by a therapist for each of the targeted outcomes, such as shoulder or hand voluntary functional movements, standing, walking, and bladder or sphincter control. Baseline measures are repeated monthly for at least 3 months until any changes reach a stable plateau 15. Postintervention rehabilitation is provided for at least 6 months at a minimum of 1 hour, 3 times a week for each targeted motor or other outcomes. Measures of how much and what type of practice subjects performed on their own are logged 16. Group statistics that compare pretherapy to posttherapy measurements are not as essential a feature of the uncontrolled case study design as clinical meaningfulness. The reader must be able to examine the raw scores for each subject in relation to clinical characteristics. Certain gains can be considered remarkable, such as recovery of hand movements in an ASIA A C5-or C6-level patient more than 3 months after a traumatic SCI 8 17. The interpretation of the data is conservative and realistic, not a selection of anecdotes. Any gains ought to be attributable to the cellular intervention; a modest change in quality of life or disability as assessed by the subject does not substitute for a quantifiable measurement of impairment by an expert 18. Red flags that strain the legitimacy of the report's approach to patient care and ethical standards include the following:
• significant details about the above criteria are absent,
• adverse responses occur that reduce the patient's quality of life or degrade existing impairments and disability, but the intervention continues to be offered, • after 10 similar subjects have received the intervention and no measure of gain is found, the investigators continue to add patients with the same characteristics and use the same procedures, and • after a subgroup of even 2 of 10 similar subjects have been reported to regain unexpected function by a reproducible measure, the investigators do not proceed with a gold-standard randomized trial in some cases. No adverse responses, including fever, spinal cord infection, functional deterioration, or mortality were associated with the procedure per the report, and 117 patients were said to have improved their American Spinal Injury Association (ASIA) impairment scores (AIS) and degree of completeness, usually within only 2 to 3 days of the procedure. An independent examination of 7 patients who underwent Huang's procedure, however, found that some patients had good enough presurgery motor function to walk, entry criteria were far broader than reported in the publication, all subjects paid for their intervention, and that 5 patients encountered serious medical complications, including aseptic meningitis, meningoencephalitis, pneumonia, and gastrointestinal bleeding. 13 None of the 7 had an increase in sensorimotor function or functional ability. Huang et al have said that patients who received considerable postoperative rehabilitation tended to improve compared with those who had little or no therapy. The Huang group continues to intervene in patients but refuses to participate in a randomized clinical trial. Lima et al 14 in Portugal initially reported 7 patients who received autologous pieces of olfactory mucosa placed into the spinal cord after removal of local scar tissue at 6 months to 6.5 years postinjury. The tissue cells were well defined. Patients were assessed preoperatively and followed for 18 months. The transplant procedure was considered safe, with minimal adverse outcomes, for example, temporary pain for 2 to 3 months in the trunk and lower limbs in 2 patients. In all, 6 patients gained sensory and motor function, and 1 lost sensation but gained motor function as measured on components of the AIS scale. Two patients changed their ASIA grade from A to C. Some patients improved their bladder and bowel control. Thus, information about safety, but not about efficacy, was provided, in that no comparison group, outside assessors, or rehabilitation were included.
Chhabra et al 15 in India aimed to use the published procedures of Lima et al. They found modest adverse responses in 5 chronic ASIA A subjects, including more neuropathic pain in one, a modest decline in sensation in one, an increase in the length of myelomalacia in a few, and development of a syrinx in 1 patient. Remarkably, olfactory mucosa tissue was confirmable by histopathology in only 3 participants. The estimation of the number of cells transplanted was also not established. No rehabilitation was provided, and no improvements related to the interventions were appreciated. This trial adds to our understanding of the complexity of reproducing another group's procedures and results and to the potential of the intervention to have a negative impact.
In their largest study, Lima et al 3 transplanted cells from autologous olfactory mucosa into a debrided spinal cord lesion from trauma in chronic paraplegic subjects. The tables in this publication reveal much of the information from every subject that a reader would need to be able to appreciate clinical characteristics and the changes over time for each prospectively planned clinical outcome. Methods to examine for additional tissue damage caused by the surgical procedures, inflammation, and possible tumor formation were limited, as expected, to any evolution of the MRI signal in relation to signs of postoperative clinical deterioration. Listed adverse reactions included a case of aseptic meningitis. Olfaction recovered despite the nasal procedures. The investigators reported instances of remarkable gains in motor function and some instances of regaining the ability to stand or take slow, effortful steps with assistive devices. These gains, however, were tied to extensive postoperative rehabilitation for standing and walking. Indeed, a potential association was drawn between the type of physical therapy and better outcomes. A limitation in the design, as reported, was that all subjects received preoperative rehabilitation, but the duration and intensity varied considerably. It is not clear that a plateau of function was reached by all prior to entry. As in the Huang et al 11, 12 reports, postoperative rehabilitation was highly associated with gains in "responders," which also means that preoperative rehabilitation to reach a clear plateau in gains is an imperative feature of future designs. 2 Is the basis for described gains from the cellular intervention a result of training-induced recovery or of new modes of compensation? 16, 17 Letters to the editor in this issue admonish Lima et al for their study procedures and report; Lima offers rebuttals. 18 A study design that reduced the chance of bias would have cut short such controversy and acrimony about the reported changes in motor scores and the basis for the new ability to stand and take slow steps (see video on the NNR Web site). The case series does not need more entries. Enough has been learned to enable the next critical step for this group, which is an overdue efficacy trial that compares surgical manipulation and cell injection with a sham intervention, with ongoing rehabilitation. Also, walking-related outcomes were sought in this case series. This functional gain seems a far less likely consequence for a patient with a complete cervical lesion; greater use of upper-extremity muscle groups that are 2 levels below a complete SCI would be a more natural therapeutic target. Reports in animal models of repair and in patients with serious SCI, however, do raise some basis for a neural substrate that could allow locomotor gains by transplantation that augments task-related practice. [19] [20] [21] Human bone marrow-derived stromal/stem cells (BMSCs) have been associated with immune, growth factor, neurite outgrowth, and behavioral changes when injected into the cord. 22, 23 Geffner et al 24 in Ecuador described 4 patients who received injections of autologous BMSCs within 40 days of onset and 4 who were >6 years from onset. As in the study by Lima et al, 14 scar tissue was removed and the cord untethered. Safety and feasibility were suggested. Before the study, the authors were aware that survival and engraftment of the cells appeared to be more likely in acute compared with chronic injuries, based on animal models. They also mentioned further injections of BMSCs in 52 subjects via multiple routes-directly into the spinal cord, directly into the spinal canal, and intravenously-with subsequent minor adverse events and possible improvement in quality of life. This vague information leaves the reader in a muddle. Clearly, this group is overdue in settling on a specific procedure in subjects with well-defined characteristics and conducting a randomized clinical trial that includes rehabilitation efforts. Further reports of cases would be superfluous.
Yoon et al 25 also transplanted BMSCs, along with the administration of granulocyte macrophage-colony stimulating factor, in a phase I/II open-label and nonrandomized study of 35 complete SCI patients. The BMSCs were injected into the surrounds of the SCI site within 14 days in 17 patients, between 14 days and 8 weeks in 6, and at more than 8 weeks in 12. In the casecontrol group, 13 patients were treated with conventional decompression and fusion surgery without BMSC transplantation. Unlike in the Geffner et al 24 cases, no significant improvement was observed in the chronic treatment group.
In this issue of NNR, Nirmeen et al report on a study in which 44 Egyptian subjects repeatedly received intrathecal BMSC for chronic complete SCI. 4 There were 20 subjects who refused the procedure and had similar baseline features; they served as case controls, which added some contrast for interpreting the results. Concerns can be raised about the conceptual basis for intrathecal administration, especially in patients with chronic SCI, inclusion of patients with myelitis, and the continuation of the procedure out to 44 patients. The main scientific value, however, is in the description of adverse reactions, including a high incidence of neuropathic pain with each injection, induction of spasticity, and an exacerbation induced in a patient with postinfectious myelitis. Any gains cannot be attributed to the cellular procedure; rehabilitation may have accounted for some of the minor motor improvements in both groups. This publication, then, shines light on adverse responses and, with its quasi control group, shows no likelihood of efficacy. But some chronic patients do make small improvements if given additional rehabilitation.
Recommendations
Based in part on these published experiences, the criteria listed in Table 1 for cell transplanters should pose neither a burden on the time of investigators and participants nor much of a hurdle in terms of cost and effort.
One immediate conclusion from reviewing these phase I/II trials for chronic SCI is that several strategies should stop and others require close scrutiny. No additional patients should be treated by these investigators outside of a phase III design with assessment for possible longitudinal changes by an independent blinded observer and data management team, as well as inclusion of an appropriate control group. This approach helps ensure that patients will have the opportunity to possibly benefit from ethically conducted research and that researchers and society can judge whether the cellular strategy is clinically effective, based on evidence rather than case anecdotes. 26 Although a series of case studies has its place, journals, institutional review boards, clinicians, and patients must continue to push for trials that can establish or refute the efficacy of each proposed cellular intervention for SCI.
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